Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…

Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…

Beyond 20 Years: What Actually Determines a Drugs Market Exclusivity
Most people think drug exclusivity is a simple clock: 20 years from filing, then the floodgates open. In reality, the timeline is more like a chess matchplayed across patents, regulat…

Pharma mega-deals dont happen because of hype. They happen because of exclusivity.
Behind every headlinewhether its a blockbuster acquisition, a licensing windfall, or a portfolio swapis a quiet, high-stakes question: How long can the buyer keep compet…

Drug Patent Cliff Forecasting: How to Predict Price Erosion Before It Happens
The market doesnt wait for you to notice the cliff.
One day, a blockbuster is protected by patents and exclusivity. The next, generic and biosimilar entrants arriveoften fast…

Post-approval is where many drug strategies quietly fail.
Youve secured approvalcongrats. But the real test begins the day the label goes live. In the months and years after launch, your product is exposed to a different kind of risk: regulatory challe…

Post-approval is where the real IP game starts.
Most teams obsess over getting to approval—then quietly assume the hard part is over. It isn’t. In the months and years after launch, your product becomes a target: for generic challengers, for “evergre…

Pharma patent strategy is supposed to be about protecting exclusivity.
But in 2026, protecting often means something more specific: defending your position without triggering the very lawsuits youre trying to avoid.
That tensionbetween aggressive enfor…

Humira to Keytruda: The Blueprint for Surviving the Composition-of-Matter Cliff
The composition-of-matter cliff isnt a metaphor. Its a calendar.
One day, a blockbusters patent moat is intact. The next, the market starts pricing in generic and biosimila…

Pharmas patent cliff isnt just about expiration dates. Its about how those dates are engineered.
For years, the industry has treated method-of-use patents like a footnotesomething technical, something legal, something that happens in the background whi…